Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Treats blood vessel disorders in the eye that are caused by conditions such as macular degeneration (a gradual loss of vision caused by aging), myopia (nearsightedness), or ocular histoplasmosis (a fungal infection of the eye).

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 11

Age-related macular degeneration: What can photodynamic therapy do?

Photodynamic therapy can slow down the development of certain damage to the retina occurring with age for some people with age-related macular degeneration, but it cannot reverse existing visual impairment.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: July 14, 2011

Fact Sheet: Age-related macular degeneration

It is a normal part of ageing: with the years, our sight slowly gets weaker. But for some people, it is worse than that and they develop eye disease. One of the problems that can cause vision loss is so-called macular degeneration. In industrialized countries, it is the most common cause of sight loss in older people. There is no cure for this condition, but for some people it is possible to slow down its progress.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: May 16, 2013

Screening for Visual Impairment in Older Adults: Systematic Review to Update the 1996 U.S. Preventive Services Task Force Recommendation [Internet]

Impaired visual acuity is common in older adults. Screening for impaired visual acuity in primary care settings could identify older adults who are unaware of or do not report vision problems, and lead to interventions to improve vision, function and quality of life.

Evidence Syntheses - Agency for Healthcare Research and Quality (US).

Version: July 2009
Show search results within this document

Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation

Age-related macular degeneration (AMD) is a major cause of blindness affecting the central portion of the retina (the macula). Wet AMD is one form of the condition and involves the formation of neovascular membranes. It is through the leakage and bleeding of these blood vessels that vision loss, which is usually irreversible, occurs. Wet AMD can be further subdivided into classic and occult and it is the classic form that is more threatening to sight. The prevalence of wet AMD has been estimated at 3 per 1000 at age 60-64 years and 117 per 1000 at 90 years and over. There are approximately 50 new cases of classic neovascular membranes per year in a typical health authority of population 500,000.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Evaluation, Trials and Studies Coordinating Centre (UK).

Version: 2003

Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation

The review assessed the clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration. The authors concluded that verteporfin is effective in reducing visual deterioration. The conclusion is reliable but the treatment is also associated with adverse events.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2003

Photodynamic therapy for treating age‐related macular degeneration

Photodynamic therapy involves injecting a photosensitive chemical (verteporfin) into the blood stream then radiating light onto the affected area of the retina as the chemical flows through the eye. The chemical is activated enough to treat neovascular or "wet" age‐related macular degeneration by sealing the new blood vessels at the back of the eye. This review includes four randomised trials involving 1429 participants. All four trials compared verteporfin therapy to 5% dextrose water (placebo treatment). Photodynamic therapy reduces the risk of vision loss caused by "wet" age‐related macular degeneration. More people treated with verteporfin also experienced improvements in vision compared to the placebo group, however, the absolute numbers experiencing vision improvement after this treatment was low (80 per 1000). A small number of people may experience acute vision loss within one week after treatment (in approximately 1 in 100 people) and infusion related back pain can occur (in approximately 1 in 50 people).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Pegaptanib: a novel approach to ocular neovascularization

OBJECTIVE: To review pegaptanib, a novel aptamer for the treatment of age-related macular degeneration (AMD).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

This review evaluated clinical and cost effectiveness of ranibizumab and pegaptanib for subfoveal choroidal neovascularisation associated with wet age-related macular degeneration. Patients with age-related macular degeneration of any type of lesion benefited from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or photodynamic therapy. These conclusions are likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

Age-related macular degeneration (AMD) causes loss of central vision and is one of the leading causes of irreversible sight loss among adults registered blind. The decrease in vision is associated with a loss of independence, an increased risk of depression, falls and fractures and a decrease in health-related quality of life. There are different types of AMD, which have different manifestations, prognoses and treatment strategies. Neovascular or wet AMD has a more variable course than other types and can progress much more quickly. Neovascular AMD is due to choroidal neovascularisation (CNV), which can be subdivided into different disease types according to its appearance on fluorescein angiography: 100% classic, predominantly classic (>50% classic), minimally classic (<50% classic) or occult with no classic. AMD lesions can also be classified according to where they occur in relation to the fovea: subfoveal, juxtafoveal or extrafoveal. Geographic atrophy (or dry AMD) is associated with gradual, progressive loss of visual function, and is not considered in this report.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Evaluation, Trials and Studies Coordinating Centre (UK).

Version: 2008

Skin Cancer Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of skin cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: October 25, 2013

Fact sheet: New drugs for age-related macular degeneration

In industrialized countries, age-related macular degeneration (AMD) is the most frequent cause for sight loss. People with AMD gradually lose some or all of their central vision. That means they can only see the outlines of objects clearly, but not the things they are looking at directly or the details that they want to focus on. Many will eventually lose most of their sight. There are now treatments that help reduce the damage to eyesight caused by one type of AMD, “wet” AMD. This fact sheet provides information about new drugs that are the most effective known treatments for this condition. You can learn more about how the eye works, what happens with AMD and other treatments in our feature on AMD.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: July 14, 2011

Systematic Reviews in PubMed

See all (43)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...